EMERGE- A Study to Evaluate the Effectiveness and Safety of a Medication (Aducanumab) in Those with Early Alzheimer's
Official Title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease Alternate Official Title: 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)
Purpose
The EMERGE study will assess the safety and potential effectiveness of an investigational medication to determine whether it can slow the progression of symptoms in early Alzheimer's Disease, such as memory loss.
Find on CT.gov- https://clinicaltrials.gov/ct2/show/study/NCT02484547?term=EMERGE&rank=…
Could this study be right for you?
In order to qualify you must:
- Be between 50-85 years of age
- Be experiencing symptoms that might be related to early Alzheimer's disease, such as problem with memory or thinking clearly
Additional eligibility criteria will be explained by study staff contact.